跳至主要内容
临床试验/JPRN-jRCTs031180191
JPRN-jRCTs031180191已完成未知

The clinical trial to evaluate the efficacy of [11C]K-2 in refractory epilepsy patients undergoing anterior temporal lobectomy

Miyazaki Tomoyuki0 个研究点目标入组 8 人开始时间: 2019年3月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
8

研究概览

简要总结

In the primary endpoint, we examined the specificity of AMPA-PET in the human brain and the correlation coefficient between the amount of AMPA receptor protein expressions in the surgical specimen and AMPA receptor densities showed a high value of 0.846 or 0.891. These results sugeest that AMPA receptor densities in the living human brain can be measured with high quantitativeness by AMPA-PET. [11C]K-2PET was generally safe.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1.refractory epilepsy patients(mesial temporal lobe epilepsy)
  • 2.patinets for anterior temporal lobectomy(ATL)
  • 3.patients who are without cerebral surgery on the same side of ATL
  • 4.patients who are 20 years or older
  • 5.patients who can consent to this study by oneself

排除标准

  • 1.patients who have significant abnormalities insides the brains
  • 2.patients who have experienced the electric stimulation therapy
  • 3.patients who undergo artificial dialysis
  • 4.patients who have severe liver dysfunction
  • 5.patients who have tatoo
  • 6.claustrophobic patients
  • 7.breast-feeding mothers, expecting mothers, females who desire to be a mother
  • 8.patients who desire to bear a child within this study period
  • 9.patients who take Fycompa
  • 10.patients who underwent nuclear medicine examination within one-week before this registarion
  • 11.patients who underwent other clinical trials using unapproved nuclear medicine examination within six month before this registarion
  • 12.patients who underwent other clinical trials within 12 weeks before this registarion
  • 13.patients whom study doctors consider unappropriate

研究者

发起方
Miyazaki Tomoyuki

相似试验